Skip to content
    AXGN
    Earnings call· Jun 2026(Q2 FY26)

    Axogen Q2 FY26 earnings call AXGN

    Jul 29, 2026 Source

    Executive summary

    Axogen Q2 FY26 — Strong Revenue Growth Driven by Breast Business and Sales Force Productivity

    Axogen delivered strong Q2 FY26 results, driven by robust demand for Avance, particularly in the Breast market, and effective sales force expansion. The company raised its full-year revenue guidance, reflecting confidence in its commercial execution and market development strategies. While gross margin faced near-term pressure from product mix, management is implementing pricing and production efficiency initiatives to address this, maintaining a positive long-term outlook for profitability and market expansion.

    Highlights

    5

    • Total revenue grew 23.1% year-over-year to $69.7 million, reflecting broad-based growth across all target markets.

    • Breast business revenue was up 47% year-over-year in H1 2026, contributing approximately two-thirds of the quarter's growth.

    • Adjusted net income improved $3.1 million sequentially to $7.3 million, demonstrating enhanced profitability.

    • Active surgeon count increased by more than 210 year-to-date, with over 135 added in high-potential accounts.

    • Full-year 2026 revenue guidance was raised to at least $279 million, representing at least 24% growth.

    Concerns

    3

    • Gross margin declined to 72.7% from 74.2% YoY, primarily due to product mix with higher-cost longer Avance grafts for Breast business.

    • Full-year 2026 gross margin guidance was lowered to at least 73% from prior expectations.

    • Aetna's review for Avance commercial payer coverage is ongoing, delaying expected favorable decision.

    Guidance & targets

    5
    CategoryTargetConfidence
    Full-year 2026 Gross Margin
    at least 73%
    high materiality
    High
    Full-year 2026 Revenue Growth
    at least 24%
    high materiality
    High
    Full-year 2026 Revenue
    at least $279 million
    high materiality
    High
    Full-year 2026 Free Cash Flow
    positive
    medium materiality
    High
    Long-term Financial Framework Update
    updated framework to be provided
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Breast
    Led growth, contributing approximately two-thirds of total Q2 growth. Year-to-date growth was 47% year-over-year. This market is still considered early in its development but is becoming a larger part of the overall mix.
    Active breast programs: 215Increase in active breast programs YoY: 40Active surgeons: 560Increase in active surgeons YoY: 150
    		—47%——
    Extremities, OMF & Head and Neck and other indications
    Combined, these segments delivered solid 15% year-over-year growth through the first half of 2026. Extremities sales were less than 50% of total sales for the first time.
    		—15%——

    Operational metrics

    18
    Revenue
    $69.7 millionup 23.1% YoY
    Q2 FY26

    Reflecting broad-based growth across all three target markets.

    Adjusted Net Income
    $7.3 millionup $1.6 million YoY
    Q2 FY26

    Compared to $5.7 million or $0.12 per share in Q2 2025. Adjusted for stock-based compensation and loss on debt extinguishment.

    Adjusted EBITDA
    $8.4 milliondown $0.9 million YoY
    Q2 FY26

    Compared to $9.3 million in Q2 2025 (16.3% of revenue). Adjusted for stock-based compensation and loss on debt extinguishment.

    Cash, Cash Equivalents, Restricted Cash and Investments
    $113.4 million
    as of June 30, 2026

    Balance at the end of the second quarter.

    Gross Margin
    72.7%down 150 bps YoY
    Q2 FY26

    Compared to 74.2% in Q2 2025. Less than internal projections due to higher-cost Avance and faster growth of long-length Avance for Breast business.

    Avance Revenue Contribution
    65%up from ~60% in 2025
    Q2 FY26

    Avance continues to be a primary driver of revenue growth.

    Active Surgeon Count
    more than 210increase
    YTD FY26

    Exceeded plan for active surgeon growth in 2026.

    Commercial Organization Headcount
    172
    Q2 FY26

    Includes sales representatives, market development managers, and regional directors.

    High Potential Accounts Revenue Contribution
    60%
    YTD FY26

    High potential accounts continue to be a primary engine for revenue growth.

    Active High Potential Accounts
    690up 11 YTD
    Q2 FY26

    Reflects continued engagement and growth in key accounts.

    Non-High Potential Accounts Revenue Contribution
    40%
    YTD FY26

    Growth in these accounts reflects growing awareness and adoption of nerve care.

    Professional Education Programs Conducted
    9
    YTD FY26

    Across all target markets to train surgeons.

    Operating Expenses
    $52.8 millionup from $40.3 million YoY
    Q2 FY26

    Driven primarily by compensation cost and stock-based compensation expense.

    Sales and Marketing Expenses
    44.2%increased 2.2 percentage points YoY
    Q2 FY26

    Reflects investments in commercial strategy to support market development.

    Research and Development Expenses
    $8.6 millionincreased 25.3% YoY
    Q2 FY26

    Compared to $6.9 million in Q2 2025 (12.1% of revenue). Essential for developing clinical evidence and innovation.

    General and Administrative Expenses
    $13.4 millionincreased 38.4% YoY
    Q2 FY26

    Compared to $9.7 million in Q2 2025 (17.1% of revenue).

    Loss on Extinguishment of Debt
    $16.8 million
    Q1 FY26

    One-time loss incurred in January, impacting Q1 net loss.

    Long-length Avance Demand Exceeding Expectations
    approximately 14%
    Q2 FY26

    Primarily stemming from the growth of the Breast business, this exceeded internal expectations and impacted gross margin.

    Industry KPIs

    3
    MetricValueDetails
    FCF conversion leverage guidancepositive
    Sales force commercial capacity build172representatives
    Pivotal trial clinical evidence milestonesREPOSE study published

    Deals & partnerships

    1
    Trace BiosciencesStrategic investment in nerve-specific imaging technology company

    Axogen acquired a minority ownership stake, including a limited right of first refusal, in Trace Biosciences. Trace's Nervetrace technology is designed to help surgeons visualize nerves in real time. This investment supports advancement through Phase II and III clinical trials toward an NDA.

    Risks & headwinds

    3
    Gross margin pressure from product mixRemainder of FY26

    Gross margin declined 150 bps YoY to 72.7% in Q2 FY26, and full-year guidance lowered to at least 73%.

    Mitigation: Implementing pricing actions and production efficiency initiatives, including increasing graft yields for long-length Avance. These measures will take time to implement and will not affect 2026 forecasted product mix.

    Delay in Aetna commercial payer coverage decisionOngoing, potentially 6-12 months for resolution

    Aetna remains the largest commercial payer not yet covering Avance. Expected update in June did not occur.

    Mitigation: Engaging with Aetna, educating them with world-leading surgeons. Optimistic that Aetna is taking time to 'get it right'. No significant increase in denials observed in practice.

    Impact of Elevance gap length restrictionNext 6-12 months, potentially annual update next year

    Policy has a gap length restriction.

    Mitigation: Educated Elevance team with world-leading surgeons. Hopeful for resolution. Not hearing about a lot of Elevance denials in practice.

    What to watch in Q3 FY26

    5

    Prostate program data release

    Q3 FY26 earnings call for strategy, Q4 FY26 for detailed update
    CurrentEarly data looking good, trends positive
    TargetDetailed update on strategy and initial clinical data

    Why it matters

    This program could open a significant new market for Avance, addressing a meaningful unmet need in post-prostatectomy patients.

    We expect to share more on the next phase of our strategy during our third quarter earnings call. What we continue to hear through our surgical experience program is that there is a meaningful unmet need.

    Q&A highlights

    7

    Despite strong Breast growth, Q2 revenue growth decelerated from Q1. Can you provide more detail on the growth of other markets (Extremities, OMF & Head and Neck) for Q2 specifically?

    Management stated they would not break out other segments individually but confirmed that Extremities and OMF & Head and Neck are growing consistent with prior comments and 'handsomely' on their respective bases.

    “We're not going to break out the other segments as we are now Breast going forward. However, the other markets are growing consistent with prior comments. So relatively different bases, Extremities being the largest; OMF, Head and Neck being smaller; but all the markets are growing handsomely.”

    asked by Michael Sarcone · answered by Michael Dale

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Priorities and Performance Overview

    Axogen's Q2 FY26 performance reflects disciplined execution against its six strategic priorities, resulting in 23.1% year-over-year revenue growth. The company is exceeding goals for customer creation, surgeon activation, new account expansion, and patient awareness across Extremities, OMF & Head and Neck, and Breast markets. This broad-based growth, particularly strong in Breast, reinforces the appropriateness of the strategic plan and led to an increased full-year revenue guidance.

    02

    Market Development and Commercial Expansion

    The company's market development efforts are yielding positive results, with the Breast market growing 47% year-over-year in H1 2026, driven by increased commercial capacity, surgeon training, and expanded coverage. Axogen ended Q2 with 172 sales representatives, adding 15 year-to-date, including 9 in Extremities and 6 in Breast. The return on investment in sales force expansion is strong, validating its role in market development and customer creation. High-potential accounts continue to be a primary growth engine, representing 60% of total revenue and growing 20% year-over-year in productivity.

    03

    Evidence Generation and Payer Coverage

    Axogen continues to advance its standard of care strategy through evidence generation and coverage development. Commercial payer coverage for Avance is approximately 86% of covered lives in the US, with Aetna's review ongoing. Key studies like REPOSE (Axoguard Nerve Cap) and RESTORE (Avance vs. sural nerve autograft) are progressing, strengthening the clinical evidence base. The Embrace study for breast reconstruction neurotization is also on track for initiation later this year, highlighting the commitment to high-quality clinical evidence.

    04

    Innovation and Strategic Investment

    The company made a strategic minority investment in Trace Biosciences, acquiring a limited right of first refusal for its Nervetrace technology. This nerve-specific imaging technology is designed to help surgeons visualize nerves in real-time, complementing Axogen's repair platform. The investment supports advancement through Phase II and III clinical trials, aligning with Axogen's strategy to expand leadership in peripheral nerve care while maintaining capital discipline. The prostate program is also progressing, with clinical development on plan and data expected in Q3, focusing on addressing unmet needs in erectile dysfunction and incontinence post-prostatectomy.

    05

    Gross Margin Dynamics and Mitigation

    Gross margin for Q2 FY26 was 72.7%, a decrease from 74.2% YoY and below internal projections. This was primarily due to a product mix shift, with the Breast business accelerating faster than planned and relying more heavily on longer Avance grafts, which carry higher production costs. Management plans to address this through pricing actions and production efficiency initiatives, including increasing graft yields for long-length Avance. However, these measures will take time to implement, leading to an updated full-year gross margin guidance of at least 73%.

    AI-generated summary of the company’s earnings call. Not investment advice.